Antisoma PLC Announces Further Data from ASA404 Ovarian Cancer Trial

LONDON, UK--(MARKET WIRE)--Jul 12, 2007 -- London, UK, 12 July 2007 - Cancer drug developer Antisoma plc (LSE: ASM, US OTC: ATSMY) today announces new data from its phase II trial of ASA404 in recurrent, platinum-sensitive ovarian cancer. This trial compares patients receiving ASA404 plus chemotherapy (n=37) with patients receiving chemotherapy alone (n=38). The main findings are as follows:
MORE ON THIS TOPIC